Product Program year 2022 Source: CMS Open Payments

Zoledronic Acid

Drug Endocrinology

NDC 43598-330-11

Open in the dashboard

General payments

$25

1 payment

Research payments

$0

0 payments

Through program year 2022, $25 in general payments and $0 in research payments were reported against Zoledronic Acid (Endocrinology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2022 General $25 1

Breakdown

Who paid General payments · program year 2022
  1. Dr.Reddy's Laboratories,Inc. $25 1 payment
Top recipients General payments · program year 2022
  1. Hal Gerstein Hematology & Oncology · Great Neck, NY $25 100% · 1 payment

Each share is of general payments naming this product in 2022.

Specialties paid General payments · program year 2022
  1. Hematology & Oncology Internal Medicine $25 100% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2022
  1. New York $25 100% · 1 recipient

Each share is of general payments naming this product in 2022 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

7,407

Prescriptions dispensed, refills included

Drug cost

$993,389

Paid at the pharmacy, in all

Medicare Part D drugs matched to Zoledronic Acid, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Zoledronic Acid Zoledronic Acid/Mannitol-Water Same name 177 4,574 $683,058
Zoledronic Acid Same name 104 2,640 $280,656
Zoledronic Acid Zoledronic Ac/Mannitol/0.9nacl Same name 10 193 $29,675

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 200 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Samy Metyas Rheumatology CA 166 $19,670 None on record
Srikanth Naramala Rheumatology CA 149 $15,406 None on record
Ana Ballester Fiallo Rheumatology TX 144 $22,818 None on record
Gopal Kunta Medical Oncology FL 126 $11,806 None on record
Dirk Davidson Medical Oncology TN 116 $21,995 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 200 with Patron
1 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record